GlassScriptPhysician profile
Abdul Kadir
NPI 1548312390
$6,748.43
in general payments reported to CMS, 2019-2025
39 companies · $408 in 2025
The $408 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $1,046 · 2021: $1,770 · 2022: $1,423 · 2023: $855 · 2024: $427 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $849.98 | 2021-2025 | |
| Ucb, INC. | $825.91 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $572.13 | 2019-2022 | |
| Biogen, INC. | $570.44 | 2019-2023 | Vumerity, Tysabri |
| Supernus Pharmaceuticals, INC. | $523.12 | 2019-2025 | Qelbree |
| Novartis Pharmaceuticals Corporation | $429.79 | 2019-2025 | |
| Celgene Corporation | $355.77 | 2020-2023 | Zeposia |
| Sk Life Science, INC. | $322.75 | 2020-2025 | |
| Genentech USA, INC. | $268.04 | 2019-2024 | Ocrevus, Enspryng |
| Argenx US, INC. | $184.89 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $156.21 | 2019-2024 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $136.81 | 2022-2025 | Hyqvia |
| Emd Serono, INC. | $132.09 | 2019-2021 | |
| Amgen INC. | $125.64 | 2019-2025 | Uplizna |
| Biohaven Pharmaceuticals, INC. | $114.50 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Kadir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.